Evidence map›Paper›PMID 41293824›Full record

Trial reportJournal of cosmetic dermatology2025

Enhancing Outcomes of Procedure Pairing With Next Generation Regenerating Skin Nectar With TriHex+ Technology.

H Ray Jalian, A Jay Burns, Nazanin Saedi, Christopher Robb, Roy G Geronemus, Kian Karimi, Faiza Shafiq, Tiffany Robison, Lora Colvan, Alan D Widgerow

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

H Ray JalianRebecca Fitzgerald MD Dermatology, Los Angeles, California, USA.
A Jay BurnsResurrect Skin MD, Dallas, Texas, USA.
Nazanin SaediDermatology Associates of Plymouth Meeting, P.C, Plymouth Meeting, Pennsylvania, USA.
Christopher RobbSkin and Allergy Center, Spring Hill, Tennessee, USA.ORCID https://orcid.org/0000-0002-5617-2798
Roy G GeronemusLaser & Skin Surgery Center of New York, New York, New York, USA.
Kian KarimiRejuva Medical Aesthetics, Los Angeles, California, USA.
Faiza ShafiqDirector of Clinical Research, Alastin Skincare, Inc. a Galderma Company, Carlsbad, California, USA.
Tiffany RobisonClinical Research Manager, Alastin Skincare, Inc. a Galderma Company, Carlsbad, California, USA.
Lora ColvanR&D Consultant, Alastin Skincare, Inc. a Galderma Company, Carlsbad, California, USA.
Alan D WidgerowDivision Chief Research, Professor Plastic Surgery, Center for Tissue Engineering, University of California Irvine, Chief Scientific Officer Galderma., Irvine, California, USA.ORCID https://orcid.org/0000-0002-5705-8073

Funding

Alastin Skincare Inc, a Galderma company
6 · The paper itself

Abstract

backgroundRegenerating Skin Nectar with TriHex+ Technology (Nectar 2.0; Alastin Skincare Inc., Carlsbad, CA) is a next-generation anhydrous serum reformulated with Octapeptide-45 to improve skin healing and hydration. Clinical trials and case studies assessed the safety, effectiveness, and patient satisfaction of Nectar 2.0 across various aesthetic procedures, including nonablative and ablative laser treatments, as well as microcoring technology.

methodsA multimodal clinical approach was used, including a randomized, double-blind, split-face study for nonablative laser procedures, an in-use study assessing skin barrier function and hydration, and case studies for ablative laser and Ellacor microcoring treatments. Investigator and subject assessments, standardized photography, and bioinstrumentation measurements (TEWL and Corneometry) were utilized to evaluate outcomes.

resultsNectar 2.0 showed superior outcomes in reducing edema and enhancing tactile roughness and fine lines in nonablative laser procedures. In ablative and microcoring treatments, faster healing, less crusting, and decreased exudation were noted, along with higher patient satisfaction compared to the control. Bioinstrumentation confirmed statistically significant improvements in skin barrier recovery and hydration over 14 days. The product was well tolerated.

conclusionRegenerating Skin Nectar with TriHex+ Technology Serum (Alastin Skincare Inc., Carlsbad, CA) has proven to be a safe and effective periprocedural skincare solution that enhances healing, improves skin quality, and increases patient satisfaction across various aesthetic procedures. Its benefits are especially significant in deeper treatments, supporting its widespread use in clinical practice.

Indexed as

Cosmetic TechniquesSkin AgingAdultDouble-Blind MethodFemaleHumansLaser TherapyMaleMiddle AgedPatient SatisfactionSkinTreatment OutcomeWound Healing

Identifiers

PMID41293824
PMCPMC12648354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.